Search by Medical Condition
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for Carcinoma, Pancreatic Ductal
- Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
- A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies
- Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer
- Using Tumor Models to Determine Treatments
- A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.
- A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
- Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
- ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)
- Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
- Study of [68Ga]FAPI-46 PET in Patients With Pancreatic Ductal Carcinoma
- Ultrasound-enhanced Uptake of Chemotherapy in Patients With Inoperable Pancreatic Ductal Adenocarcinoma
- A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China
- A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors
- The Combination Chemotherapy of SIRIOX as First- or Second-Line Chemotherapy for Pancreatic Cancer
- A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma
- A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal A
- Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors
- Parvovirus H-1 (ParvOryx) in Patients With Metastatic Inoperable Pancreatic Cancer
- Safety and Efficacy Evaluation of iAPA-DC/CTL Combined Gemcitabine Therapy on Advanced Pancreatic Cancer
- Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer
- Atu027 Plus Gemcitabine in Advanced or Metastatic Pancreatic Cancer (Atu027-I-02)
- A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors
- Amatuximab for High Mesothelin Cancers
- Chemotherapy Selection Based on Therapeutic Targets for Advanced Pancreatic Cancer
- Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.
- Efficacy Study of Gemcitabine, Paclitaxel, and Irradiation in the Treatment of Pancreatic Cancer